Intelligence Feed event · Equity · 2026-09-11

    GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff

    Question

    GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff

    Direct answer

    GSK reported 14% growth in its Specialty Medicines division during the first half of 2026, driven by uptake in HIV, oncology, and respiratory therapies. The segment now accounts for over 40% of group revenue. To mitigate future revenue erosion from dolutegravir patent expirations in the late 2020s, GSK is advancing late-stage R&D with more than 20 Phase III clinical study initiations scheduled during 2026.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-11
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff”, revision 1, evidence through 2026-09-11. https://marketontology.com/market-events/2026-09-11/gsk-specialty-medicines-grow-14-as-company-prepares-20-phase-iii-starts-ahead-of-41d248

    EQUITY
    GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff
    GSK reported 14% growth in its Specialty Medicines division during the first half of 2026, driven by uptake in HIV, oncology, and respiratory therapies. The segment now accounts for over 40% of group revenue. To mitigate future revenue erosion from dolutegravir patent expirations in the late 2020s, GSK is advancing late-stage R&D with more than 20 Phase III clinical study initiations scheduled during 2026.
    GSKGILD
    Impact
    65
    SEP 11
    SIG
    84%
    GSKGILD
    GSK Specialty Medicines Grow 14% as Company Prepares 20 Phase III Starts Ahead of Patent Cliff
    GSK reported 14% growth in its Specialty Medicines division during the first half of 2026, driven by uptake in HIV, oncology, and respiratory therapies. The segment now accounts for over 40% of group revenue. To mitigate future revenue erosion from dolutegravir patent expirations in the late 2020s, GSK is advancing late-stage R&D with more than 20 Phase III clinical study initiations scheduled during 2026.
    → Accelerated Phase III clinical trial execution provides revenue pipeline replacement for GSK ahead of dolutegravir exclusivity expiration.
    Impact
    GSK reported 14% growth in its Specialty Medicines division during the first half of 2026, driven by uptake in HIV, oncology, and respiratory therapies. The segment now accounts for over 40% of group revenue. To mitigate future revenue erosion from dolutegravir patent expirations in the late 2020s, GSK is advancing late-stage R&D with more than 20 Phase III clinical study initiations scheduled during 2026.
    Affected
    GSKGILD
    Transmission
    Accelerated Phase III clinical trial execution provides revenue pipeline replacement for GSK ahead of dolutegravir exclusivity expiration.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GSKspecialty pharmaceuticals volume growth balanced against long-term patent expiry risksMixed1-3mGSK specialty medicines grew 14% in H1 2026 while facing upcoming dolutegravir patent expiration.
    GILDcompetitive market share dynamics in commercial HIV drug treatment categoryWatch1-3mGilead competes directly in commercial HIV treatment segment alongside GSK.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month